Scalp HealthNCT07901426
Evaluation of the Scalp Skin Care Effects of Premium Revitalizing Elixir and Topical 5% Minoxidil
A study testing Base formula only, Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7 and Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7 in people with Scalp Health and Alopecia, run by Hungkuang University at 1 site in Taiwan.
Trial summary
The study aims to evaluate the efficacy of two formulations on human scalp skin against established standard treatment of 5% minoxidil and base formula (placebo). A total of 40 healthy adults, aged 18 to 60 with alopecia, baldness, or self-identified with symptoms of hair thinning will be recruited and randomly… Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Scalp Health, Alopecia, Hair Condition
- What is being tested?
- Base formula only, Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7 and Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Jun 2026to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adults of any gender from the age of 18 to 60 years (inclusive).
- Having symptoms of alopecia, baldness, or self-identified with hair thinning.
- Absence of chronic diseases, major illnesses, or allergies.
- Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant
Who cannot join
- Currently taking any medication or using any scalp care products
- Pregnant or breastfeeding
- Chronic diseases, significant illnesses, or allergic constitutions
- Currently using scalp care products
- Students or employees affiliated with the principal investigator,
- Individuals with scalp wounds
- Participated in cosmetic product testing
- Undergone scalp aesthetic treatments within the past three months.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Scalp Skin Care Effects of Premium Revitalizing Elixir and Minoxidil 5% Topical Solution
The study aims to evaluate the efficacy of two formulations on human scalp skin against established standard treatment of 5% minoxidil and base formula (placebo). A total of 40 healthy adults, aged 18 to 60 with alopecia, baldness, or self-identified with symptoms of hair thinning will be recruited and randomly assigned into four groups (n=10 for each group) receiving different formulations. Participants will use the product twice daily (once in the morning and once in the evening) for 84 days, and their scalp conditions will be assessed through skin texture tests at multiple time points. Key parameters such as sebum content, overall hair loss, hair density, scalp condition, and hair length will be measured at an interval of two weeks for a total of seven times, including baseline measurements.
Read the detailed description
This is a prospective, randomized, double-blinded, and placebo-controlled study to investigate the effects of two formulations on human scalp skin against established standard of care of topical 5% minoxidil and placebo control (base formulat).
This study enrolls 40 healthy adults aged from 18 to 60 with alopecia, baldness, or self-identified with symptoms of hair thinning.
Inclusion criteria include healthy adults defined as individuals without chronic diseases, significant illnesses (including cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant), or allergic constitutions, and who are not currently taking any medication or using any scalp care products.
Exclusion criteria include individuals who are pregnant or breastfeeding, as well as males or females with chronic diseases, significant illnesses, or allergic constitutions, currently using scalp care products, students or employees affiliated with the principal investigator, individuals with scalp wounds, those who have participated in cosmetic product testing, and those who have undergone scalp aesthetic treatments within the past three months.
The participants will be randomly assigned into five groups, with 10 individuals in each group. Group 1 uses the Base formula (including 0.1% caffeine and panthenol); Group 2 uses Base + Centella asiatica extracellular vesicles + IGF-1 \& FGF-7; Group 3 uses Base + Centella asiatica extracellular vesicles + Ginger-derived extracellular vesicles + IGF-1 \& FGF-7; Group 4 uses commericial topical 5% minoxidil. Before using the test product, all participants undergo the first scalp skin texture test. The participants will apply interventions twice daily, once in the morning and once in the evening after hair wash. Assessments will be taken for every 14 days (including baseline) for up to Day 84. The assessments consist of: (1) sebum content, (2) overall hair loss, (3) hair density, (4) scalp condition, (5) hair length, and other parameters. The Sebumeter® SM815 probe of the MPA580 device and the ScalpX Intelligent Scalp Diagnostic System will be used to measure the parameters of the study.
- Conditions
- Scalp Health, Alopecia, Hair Condition, Hair Loss, Sebum Production, Hair Health
- Being tested
- Base formula only, Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7, Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7, 5% Topical Minoxidil Solution
- Keywords
- Scalp care, Hair loss, Alopecia, Balding, Sebum production, Hair thinning, Scalp condition, Comparative study, Minoxidil, Topical application, Extracellular vesicles, Growth factors, Centella asiatica, Ginger, Cosmetics, Hair density, Herbal formulation
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Base formula onlyOther
Base formula consisting of 0.1% caffeine and panthenol. Apply 1mL evenly to the scalp twice daily, once in the morning and once in the evening (after hair wash) for 84 consecutive days.
Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7Other
Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Apply 1mL evenly to the scalp twice daily, once in the morning and once in the evening (after hair wash) for 84 consecutive days.
Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7Other
Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Apply 1mL evenly to the scalp twice daily, once in the morning and once in the evening (after hair wash) for 84 consecutive days.
5% Topical Minoxidil SolutionOther
Commercial 5% topical minoxidil solution. Apply 1mL evenly to the scalp twice daily, once in the morning and once in the evening (after hair wash) for 84 consecutive days.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Base formula only | Placebo comparator | Base formula consisting of active ingredients 0.1% caffeine and panthenol (vitamin B5). Receives: Other: Base formula only |
| Group 2: Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7 | Experimental | Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7) Receives: Other: Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7 |
| Group 3: Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7 | Experimental | Base formula plus Centella asiatica and ginger (Zingiber officinale) extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7) Receives: Other: Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7 |
| Group 4: 5% Topical Minoxidil Solution | Active comparator | Commercial topical 5% minoxidil Receives: Other: 5% Topical Minoxidil Solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sebum Content
Assess oil levels on the scalp at standardized scalp sites (left, right, and vertex). Measured with C+K Multi Probe Adaptor MPA580 system using the Sebumeter® SM815 probe based on the grease spot photometry method with the sebum measurement cassette tape.
Measured: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)
Hair length
Hair length (in cm): Measured manually with ruler at standardized scalp sites (left, right, and vertex).
Measured: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)
Hair density
Hair density (number of hairs/cm-square): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex).
Measured: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)
Hair thickness
Hair thickness (in micrometers): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex).
Measured: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)
Hair loss
Assessed by the standardized hair combing test by counting the number of hairs shed after the participants' hair was combed over a clean surface for 60 strokes.
Measured: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start1 Jun 2026
- Primary completionDec 2026 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Scalp HealthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hungkuang University
- Sponsor type
- University, hospital or other
- Collaborators
- Schweitzer Biotech Company
- Responsible party
- Principal investigator, Tsong-Min Chang, Hungkuang University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07901426
- Sponsor's protocol ID
- 26-061-A
- Status last verified
- Oct 2026
- First submitted
- 21 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chang TM, Wu CC, Huang HC, Lu JY, Chuang CH, Kao PL, Tang WH, Hsieh WJ, Liu LT, Qiu WY, Percec I. Centella asiatica L. Urb. Extracellular Vesicle and Growth Factor Essence for Hair and Scalp Health: A 56-Day Exploratory Randomized Trial. Cosmetics. 2025 Nov 10;12(6):253.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Scalp Skin Care Effects of Premium Revitalizing Elixir and Minoxidil 5% Topical Solution
- ClinicalTrials.gov ID
- NCT07901426
- Acronym / sponsor ID
- 26-061-A
- Conditions
- Scalp Health, Alopecia, Hair Condition, Hair Loss, Sebum Production, Hair Health
- Keywords
- Scalp care, Hair loss, Alopecia, Balding, Sebum production, Hair thinning, Scalp condition, Comparative study
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Hungkuang UniversityUniversity, hospital or other
- Collaborators
- Schweitzer Biotech Company
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to evaluate the efficacy of two formulations on human scalp skin against established standard treatment of 5% minoxidil and base formula (placebo). A total of 40 healthy adults, aged 18 to 60 with alopecia, baldness, or self-identified with symptoms of hair thinning will be recruited and randomly assigned into four groups (n=10 for each group) receiving different formulations. Participants will use the product twice daily (once in the morning and once in the evening) for 84 days, and their scalp conditions will be assessed through skin texture tests at multiple time points. Key parameters such as sebum content, overall hair loss, hair density, scalp condition, and hair length will be measured at an interval of two weeks for a total of seven times, including baseline measurements.
Detailed description
This is a prospective, randomized, double-blinded, and placebo-controlled study to investigate the effects of two formulations on human scalp skin against established standard of care of topical 5% minoxidil and placebo control (base formulat).
This study enrolls 40 healthy adults aged from 18 to 60 with alopecia, baldness, or self-identified with symptoms of hair thinning.
Inclusion criteria include healthy adults defined as individuals without chronic diseases, significant illnesses (including cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant), or allergic constitutions, and who are not currently taking any medication or using any scalp care products.
Exclusion criteria include individuals who are pregnant or breastfeeding, as well as males or females with chronic diseases, significant illnesses, or allergic constitutions, currently using scalp care products, students or employees affiliated with the principal investigator, individuals with scalp wounds, those who have participated in cosmetic product testing, and those who have undergone scalp aesthetic treatments within the past three months.
The participants will be randomly assigned into five groups, with 10 individuals in each group. Group 1 uses the Base formula (including 0.1% caffeine and panthenol); Group 2 uses Base + Centella asiatica extracellular vesicles + IGF-1 \& FGF-7; Group 3 uses Base + Centella asiatica extracellular vesicles + Ginger-derived extracellular vesicles + IGF-1 \& FGF-7; Group 4 uses commericial topical 5% minoxidil. Before using the test product, all participants undergo the first scalp skin texture test. The participants will apply interventions twice daily, once in the morning and once in the evening after hair wash. Assessments will be taken for every 14 days (including baseline) for up to Day 84. The assessments consist of: (1) sebum content, (2) overall hair loss, (3) hair density, (4) scalp condition, (5) hair length, and other parameters. The Sebumeter® SM815 probe of the MPA580 device and the ScalpX Intelligent Scalp Diagnostic System will be used to measure the parameters of the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 1: Base formula only | Placebo comparator | Other: Base formula onlyBase formula consisting of active ingredients 0.1% caffeine and panthenol (vitamin B5). |
| Group 2: Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7 | Experimental | Other: Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7) |
| Group 3: Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7 | Experimental | Other: Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7Base formula plus Centella asiatica and ginger (Zingiber officinale) extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7) |
| Group 4: 5% Topical Minoxidil Solution | Active comparator | Other: 5% Topical Minoxidil SolutionCommercial topical 5% minoxidil |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy adults of any gender from the age of 18 to 60 years (inclusive).
- Having symptoms of alopecia, baldness, or self-identified with hair thinning.
- Absence of chronic diseases, major illnesses, or allergies.
- Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant
Key exclusion criteria (8 listed)
- Currently taking any medication or using any scalp care products
- Pregnant or breastfeeding
- Chronic diseases, significant illnesses, or allergic constitutions
- Currently using scalp care products
- Students or employees affiliated with the principal investigator,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Base formula onlyBase formula consisting of 0.1% caffeine and panthenol. Apply 1mL evenly to the scalp twice daily, once in the morning and once in the evening (after hair wash) for 84 consecutive days. | Other | Group 1: Base formula only |
| Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Apply 1mL evenly to the scalp twice daily, once in the morning and once in the evening (after hair wash) for 84 consecutive days. | Other | Group 2: Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7 |
| Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Apply 1mL evenly to the scalp twice daily, once in the morning and once in the evening (after hair wash) for 84 consecutive days. | Other | Group 3: Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7 |
| 5% Topical Minoxidil SolutionCommercial 5% topical minoxidil solution. Apply 1mL evenly to the scalp twice daily, once in the morning and once in the evening (after hair wash) for 84 consecutive days. | Other | Group 4: 5% Topical Minoxidil Solution |
Primary outcome
Sebum Content
Time frame: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)
Assess oil levels on the scalp at standardized scalp sites (left, right, and vertex). Measured with C+K Multi Probe Adaptor MPA580 system using the Sebumeter® SM815 probe based on the grease spot photometry method with the sebum measurement cassette tape.
Hair length
Time frame: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)
Hair length (in cm): Measured manually with ruler at standardized scalp sites (left, right, and vertex).
Hair density
Time frame: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)
Hair density (number of hairs/cm-square): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex).
Hair thickness
Time frame: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)
Hair thickness (in micrometers): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex).
Hair loss
Time frame: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0)
Assessed by the standardized hair combing test by counting the number of hairs shed after the participants' hair was combed over a clean surface for 60 strokes.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- BackgroundChang TM, Wu CC, Huang HC, Lu JY, Chuang CH, Kao PL, Tang WH, Hsieh WJ, Liu LT, Qiu WY, Percec I. Centella asiatica L. Urb. Extracellular Vesicle and Growth Factor Essence for Hair and Scalp Health: A 56-Day Exploratory Randomized Trial. Cosmetics. 2025 Nov 10;12(6):253.
- Individual participant dataSharing planned: No
Related trials for Scalp Health
Recruiting
A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients
Hair Transplantation, Seborrheic Dermatitis
RecruitingObservational study
Scalp Hair Metabolomics in Severe Obesity
Obesity & Overweight, Hair Loss
Recruiting
Evaluation of the Fetal Response to Intrapartum Digital Fetal Scalp Stimulation to Identify Intrapartum Fetal Hypoxia.
Fetal Hypoxia, Fetal Monitoring
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Base formula only, Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7 and Base formula plus Centella asiatica and ginger extracellular vesicles, IGF-1 & FGF-7 in people with Scalp Health and Alopecia, run by Hungkuang University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sebum Content (time frame: Assessment conducted every 14 days from Day 0 to Day 84 (including Day 0 as baseline)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07901426, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.